ReviewBlood cancer journal2017
Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.
Review in Blood cancer journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 155 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
155 citing papers in PubMed, 2 syntheses or guidelines pooled it, 233 citations in OpenAlex.
- Efficacy and safety of CD30-targeted chimeric antigen receptor T-cell therapy for lymphoma: a meta-analysis.BMC cancer · 2026Pooled it
- Rare COVID-19 vaccine side effects got lost in the shuffle. Primary cutaneous lymphomas following COVID-19 vaccination: a systematic review.Frontiers in medicine · 2024Pooled it
- A phase 1b/2 study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.Blood advances · 2026Trial
- CD30 CAR-T cells in combination with anti-PD-1 camrelizumab in relapsed/refractory CD30Journal of translational medicine · 2026Trial
- Brentuximab vedotin for skin involvement in refractory diffuse cutaneous systemic sclerosis, an open-label trial.Rheumatology (Oxford, England) · 2025Trial
- Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30-positive cutaneous T-cell lymphoma.The Journal of dermatology · 2024Trial
- Population Pharmacokinetic Modeling and Exposure-Response Assessment for the Antibody-Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON-1 Study.Clinical pharmacology and therapeutics · 2019Trial
- Review
- BCL-2 inhibition at antiretroviral therapy initiation reduces the intact SIV reservoir in macaques.Nature microbiology · 2026Article
- Precision Medicine in Non-Hodgkin Lymphoma: Advances in BTK Inhibition, CD30-Directed Antibody-Drug Conjugates, and HDAC-Mediated Epigenetic Therapy with Pirtobrutinib, Brentuximab Vedotin, and Belinostat.Journal of clinical medicine · 2026Review
- CD30 Expression in Neoplastic Mast Cells and the Presence of CD30+, CD3+, and PAX-5+ Tumour-Infiltrating Lymphocytes as Prognostic Markers in Canine Cutaneous Mast Cell Tumours.Veterinary and comparative oncology · 2026Article
- CD80 (B7-1) as a potential therapeutic target in Epstein-Barr virus‑associated B cell diseases.Scientific reports · 2026Article
- A CD4Nature communications · 2026Article
- Beyond CD30: Dual-Targeting of Malignant and Regulatory T Cells by Brentuximab Vedotin Remodels the Lymphoma Microenvironment and Overcomes Resistance via BCL2 Inhibition in Mycosis Fungoides.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- CD30 knockout attenuates experimental colitis by reducing inflammatory cytokine production.BMC immunology · 2026Article
- A Two-Track Model of Huntington's Disease Pathology: Striatal Atrophy Mediates Maladaptive Immune Dysregulation.International journal of molecular sciences · 2026Article
- Survival Trends and Prognostic Modeling in ALK-Positive Anaplastic Large Cell Lymphoma: A Population-Based Study in the Brentuximab Vedotin Era.Cancer medicine · 2026Article
- Synergistic adverse prognostic impact of CD30 and Epstein-Barr virus in peripheral T-cell lymphoma: CD30 identifies a high-risk subgroup in Epstein-Barr virus-encoded RNA -positive patients.Annals of hematology · 2026Article
- Evolution of therapeutic paradigms in Hodgkin lymphoma: from "cure-oriented" to "functional cure".Frontiers in oncology · 2026Review
- Role of WDR66 in Stemness, Therapy Resistance and Tumor microenvironment modulation in Head and Neck Cancer.International journal of biological sciences · 2026Article
95 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD30 is a member of the tumor necrosis factor receptor superfamily. It is characteristically expressed in certain hematopoietic malignancies, including anaplastic large cell lymphoma and Hodgkin lymphoma, among others. The variable expression of CD30 on both normal and malignant lymphoid cells has focused research efforts on understanding the pathogenesis of CD30 upregulation, its contribution to lymphomagenesis through anti-apoptotic mechanisms, and its effect on cell survival. Given the restriction of CD30 to certain tumor types, the logical extension of this has been to attempt to exploit it as a therapeutic target. The efficacy of naked anti-CD30 antibodies in practice was, however, modest. Moreover, combinations with bacterial toxins and radioimmunoconjugates have also had limited success. The development of the antibody-drug compound brentuximab vedotin (BV), however, has rejuvenated interest in CD30 as a tumor target. Phase I and II clinical trials in Hodgkin lymphoma, peripheral T-cell lymphoma, cutaneous T cell lymphoma, and even CD30-expressing B-cell lymphomas, have shown the compound is well tolerated, but more importantly, able to deliver meaningful disease control even in patients with multiply relapsed or refractory disease. FDA approval has been granted for its use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. A recent phase III trial of BV in cutaneous T-cell lymphoma has confirmed its superiority to standard of care therapies. In this manuscript, we explore the history of CD30 as a tumor marker and as a therapeutic target, both in the laboratory and in the clinic, with a view to understanding future avenues for further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.